LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Inicio・Lista de Acciones・ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc

Cerrado

SectorSalud

21.95 1.76

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

21.9

Máximo

22.07

Métricas clave
By Trading Economics
Ingresos	45M 72M
Ventas	14M 279M
P/B Media del Sector	15.177 121.746
BPA	0.42
Margen de beneficio	25.761
Empleados	653
EBITDA	7.3M 48M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 meses	+44.24% upside

Dividendos
By Dow Jones
Próximas Ganancias	25 feb 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	154M 3.9B
Apertura anterior	20.19
Cierre anterior	21.95

Noticias sobre sentimiento de mercado

By Acuity

31%

69%

89 / 352 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

14.845 / N/A Soporte y Resistencia

ACADIA Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

13 feb 2026, 16:32 UTC

Ganancias

Enbridge, TC Energy Investing in Opportunities to Tap Rising Energy Demand, Boom in Data Centers -- Update

13 feb 2026, 21:57 UTC

Ganancias

Stocks Rise on Softer Inflation Data, but AI Jitters Trigger Worst Week Since November -- WSJ

13 feb 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

13 feb 2026, 21:20 UTC

Ganancias

Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More Stock Market Movers -- Barrons.com

13 feb 2026, 21:05 UTC

Adquisiciones, fusiones, absorciones

Constellation Software: Lumine Group Completes Acquisition of Synchronoss Technologies >CSU.T SNCR

13 feb 2026, 20:45 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

13 feb 2026, 20:45 UTC

Charlas de Mercado

Dollar Pares Down Early Losses -- Market Talk

13 feb 2026, 20:39 UTC

Charlas de Mercado

Potential for Mild Winter Ahead Sinks Natural Gas for Week -- Market Talk

13 feb 2026, 20:28 UTC

Charlas de Mercado

Oil Settles Week Lower -- Market Talk

13 feb 2026, 19:51 UTC

Ganancias

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13 feb 2026, 19:32 UTC

Charlas de Mercado

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13 feb 2026, 19:32 UTC

Charlas de Mercado

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13 feb 2026, 19:29 UTC

Ganancias

Big Tech's Spending Spree Could Limit Buybacks and Dividends -- Barrons.com

13 feb 2026, 18:18 UTC

Adquisiciones, fusiones, absorciones

Exxon, Walmart and 9 Other Stocks That Are Soaring Because Cash Is King Again -- Barrons.com

13 feb 2026, 17:52 UTC

Ganancias

Pinterest's Earnings Give More Proof of Meta Platform's Dominance -- Barrons.com

13 feb 2026, 17:16 UTC

Ganancias

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13 feb 2026, 17:10 UTC

Adquisiciones, fusiones, absorciones

Vibe-Coding in Gas Town? A Guide to the Software Selloff With 4 Sexy Stock Picks. -- Barrons.com

13 feb 2026, 16:59 UTC

Ganancias

AppLovin Stock Stabilizes After Selloff. Its Biggest Critic Waves the White Flag. -- Barrons.com

13 feb 2026, 16:39 UTC

Adquisiciones, fusiones, absorciones

Berkshire Might Have Sold More Apple, Bank of America Stock in Fourth Quarter -- Barrons.com

13 feb 2026, 16:11 UTC

Ganancias

Nvidia Stock Wobbles. The Focus Is Turning to Earnings. -- Barrons.com

13 feb 2026, 16:07 UTC

Charlas de Mercado

Hungarian Forint Could Rise Further -- Market Talk

13 feb 2026, 15:54 UTC

Ganancias

Detroit Automakers Take $50 Billion Hit as EV Bubble Bursts -- WSJ

13 feb 2026, 15:26 UTC

Charlas de Mercado

Indian Imports of Saudi Crude Hit Highest Since 2022 -- Market Talk

13 feb 2026, 15:01 UTC

Ganancias

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Steel Dynamics, Coinbase, DraftKings, Tri Pointe Homes, and More -- Barrons.com

13 feb 2026, 15:00 UTC

Ganancias

Expedia Falls, but Airbnb Rises. Why Online Travel Stocks Face a Tough Year. -- Barrons.com

13 feb 2026, 14:50 UTC

Charlas de Mercado

Oil Moves Lower As Market Weighs Geopolitical Risk -- Market Talk

13 feb 2026, 14:44 UTC

Ganancias

Arista Networks Stock Climbs. Why It Is Outshining Cisco. -- Barrons.com

13 feb 2026, 14:22 UTC

Charlas de Mercado

Ganancias

Global Energy Roundup: Market Talk

13 feb 2026, 14:21 UTC

Charlas de Mercado

Ganancias

TC Energy's Broadly Anticipated Results Expected To Have Neutral Response -- Market Talk

13 feb 2026, 14:13 UTC

Charlas de Mercado

U.S. Natural Gas Futures Move Lower -- Market Talk

Comparación entre iguales

Cambio de precio

ACADIA Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

44.24% repunte

Estimación a 12 meses

Media 31.17 USD 44.24%

Máximo 40 USD

Mínimo 23 USD

De acuerdo con 12 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para ACADIA Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

12 ratings

Comprar

Mantener

Vender

De acuerdo con 12 analistas que ofrecen calificaciones bursátiles a para ACADIA Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

14.845 / N/ASoporte y Resistencia

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentimiento

By Acuity

89 / 352 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.